Article
Oncology
Gerardo Rosati, Sara Lonardi, Fabio Galli, Maria Di Bartolomeo, Monica Ronzoni, Maria G. Zampino, Maria Banzi, Alberto Zaniboni, Felice Pasini, Silvia Bozzarelli, Silvio K. Garattini, Daris Ferrari, Vincenzo Montesarchio, Andrea Mambrini, Libero Ciuffreda, Francesca Galli, Valeria Pusceddu, Chiara Carlomagno, Paolo Bidoli, Domenico Amoroso, Anna M. Bochicchio, Luca Frassineti, Domenico Corsi, Domenico Bilancia, Alessandro Pastorino, Alfonso De Stefano, Roberto Labianca
Summary: Older patients receiving oxaliplatin-based adjuvant therapy have worse prognostic factors and reduced treatment compliance, leading to decreased efficacy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Takayuki Yoshino, Eiji Oki, Toshihiro Misumi, Masahito Kotaka, Dai Manaka, Tetsuya Eto, Junichi Hasegawa, Akinori Takagane, Masato Nakamura, Takeshi Kato, Yoshinori Munemoto, Fumitaka Nakamura, Hiroyuki Bando, Hiroki Taniguchi, Yasuhiro Sakamoto, Manabu Shiozawa, Masayasu Nishi, Tetsuya Horiuchi, Hisakazu Yamagishi, Junichi Sakamoto, Tsunekazu Mizushima, Atsushi Ohtsu, Masaki Mori
Summary: The study demonstrated that shortening adjuvant therapy duration from 6 to 3 months did not compromise efficacy in Asian patients with colon cancer, and also reduced the rate of long-lasting peripheral sensory neuropathy. In this setting, 3 months of CAPOX therapy is a suitable adjuvant treatment option.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Seung Tae Kim, Sun Young Kim, Jeeyun Lee, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Tae Won Kim, Yong Sang Hong, Seok-Byung Lim, Ji Yeon Baek, Jae Hwan Oh, Joong Bae Ahn, Sang Joon Shin, Sae-Won Han, Seong Geun Kim, Seok Yun Kang, Sun Jin Sym, Dae Young Zang, Yeul Hong Kim, In Sil Choi, Jung Hun Kang, Min-Ji Kim, Young Suk Park
Summary: This study suggests that reducing the duration of oxaliplatin treatment from 6 months to 3 months, in combination with fluoropyrimidine, may be an alternative adjuvant treatment option for patients with stage III colorectal cancer. The study shows comparable disease-free survival rates between the 3-month and 6-month arms, while reducing the incidence of neurotoxicity.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Wen-Kuan Huang, Wei-Pang Ho, Hung-Chih Hsu, Shu-Hao Chang, Dong-Yi Chen, Wen-Chi Chou, Pei-Hung Chang, Jen-Shi Chen, Tsai-Sheng Yang, Lai-Chu See
Summary: This study aimed to compare the risk of cardiovascular disease among different fluoropyrimidine derivatives in colorectal cancer patients. The study found that the UFT group had higher rates of heart failure and ischemic stroke compared to the other two chemotherapy groups. Therefore, careful monitoring of this subset of patients when prescribing UFT is warranted.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Kwan-Ling Yip, Tsen-Ni Tsai, I-Ping Yang, Zhi-Feng Miao, Yen-Cheng Chen, Ching-Chun Li, Wei-Chih Su, Tsung-Kun Chang, Ching-Wen Huang, Hsiang-Lin Tsai, Yung-Sung Yeh, Jaw-Yuan Wang
Summary: Metformin enhances the chemosensitivity of colorectal cancer cells to 5-fluorouracil and oxaliplatin by inducing cell cycle arrest and apoptosis through modulation of mitochondria-related proteins.
Article
Gastroenterology & Hepatology
Brendan L. Hagerty, John G. Aversa, Dana A. Dominguez, Jeremy L. Davis, Jonathan M. Hernandez, James T. McCormick, Andrew M. Blakely
Summary: In patients with stage II colon cancer, young patients frequently receive adjuvant chemotherapy while older patients rarely receive adjuvant therapy. Age is an independent factor associated with the receipt of adjuvant chemotherapy.
DISEASES OF THE COLON & RECTUM
(2022)
Article
Oncology
Xiaohong Han, Zheng Wang, Lei Zhang, Yinchen Shen, Qiaoyun Tan, Yongkun Sun, Jianfei Wang, Xiaoyan Qian, Hongying Yang, Yuankai Shi
Summary: A three-stage study framework identified a stable association of rs6891545C > A polymorphism in the SLF1 gene with the response to oxaliplatin-based adjuvant chemotherapy in patients with stage II and III colon cancer, suggesting that patients carrying the A allele had better treatment response.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Romain Cohen, Julien Taieb, Jack Fiskum, Greg Yothers, Richard Goldberg, Takayuki Yoshino, Steven Alberts, Carmen Allegra, Aimery de Gramont, Jean-Francois Seitz, Michael O'Connell, Daniel Haller, Norman Wolmark, Charles Erlichman, Alberto Zaniboni, Sara Lonardi, Rachel Kerr, Axel Grothey, Frank A. Sinicrope, Thierry Andre, Qian Shi
Summary: In patients with stage III colon cancer, the presence of microsatellite instability (MSI) in tumors may lead to improved overall survival and disease-free survival when oxaliplatin is added to fluoropyrimidine (FP) treatment.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Wen-Kuan Huang, Hung-Chih Hsu, Shu-Hao Chang, Wen-Chi Chou, Pei-Hung Chang, Sum-Fu Chiang, John Wen-Cheng Chang, Jen-Shi Chen, Tsai-Sheng Yang, Lai-Chu See
Summary: The real-world effectiveness of oxaliplatin in stage III colon cancer was not found to significantly improve survival rates. Future research should focus on identifying the specific subpopulations of patients who may benefit significantly from the addition of oxaliplatin.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Goro Nakayama, Nao Takano, Hiroya Taniguchi, Kiyoshi Ishigure, Hiroyuki Yokoyama, Hitoshi Teramoto, Ryoji Hashimoto, Mitsuru Sakai, Akiharu Ishiyama, Takashi Kinoshita, Naomi Hayashi, Masanori Nakamura, Norifumi Hattori, Yusuke Sato, Shinichi Umeda, Kei Uehara, Toshisada Aiba, Fuminori Sonohara, Masamichi Hayashi, Mitsuro Kanda, Daisuke Kobayashi, Chie Tanaka, Suguru Yamada, Masahiko Koike, Michitaka Fujiwara, Kenta Murotani, Masahiko Ando, Yuichi Ando, Kei Muro, Yasuhiro Kodera
Summary: The study suggests that intermittent use of oxaliplatin in CAPOX adjuvant therapy may reduce the occurrence of PSN, shorten the duration of treatment, and have positive effects on the efficacy and safety of colon cancer patients.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Jemma M. Boyle, Angela Kuryba, Thomas E. Cowling, Jan van der Meulen, Nicola S. Fearnhead, Kate Walker, Michael S. Braun, Ajay Aggarwal
Summary: Completing all cycles of oxaliplatin-based adjuvant chemotherapy was associated with improved cancer-specific survival in real-world practice, but patients completing less than 50% of cycles had poor outcomes.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Emily Jones, Zhigang Duan, Thinh T. Nguyen, Sharon H. Giordano, Hui Zhao
Summary: This study evaluated the patterns of different drug regimens used in adjuvant chemotherapy for high-risk stage II or III colon cancer patients, as well as their association with survival and rates of emergency room visits or hospitalizations. The study found that FLOX/OX regimen was associated with improved survival, while capecitabine regimen had the lowest rates of emergency room visits or hospitalizations.
Article
Oncology
Seohyuk Lee, Chao Ma, Qian Shi, Pankaj Kumar, Felix Couture, Philip Kuebler, Smitha Krishnamurthi, DeQuincy Lewis, Benjamin Tan, Richard M. Goldberg, Alan Venook, Charles Blanke, Eileen M. O'Reilly, Anthony F. Shields, Jeffrey A. Meyerhardt
Summary: This study aimed to evaluate the independent and interactive associations of planned treatment duration, celecoxib use, physical activity, BMI, diabetes, and vitamin B6 with Oxaliplatin-induced peripheral neuropathy (OIPN). The results showed that longer treatment cycles, lower physical activity, higher BMI, and diabetes were significantly associated with increased OIPN severity.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Katie Watts, Christopher Wills, Ayman Madi, Claire Palles, Timothy S. Maughan, Richard Kaplan, Nada A. Al-Tassan, Rachel Kerr, David Kerr, Victoria Gray, Hannah West, Richard S. Houlston, Valentina Escott-Price, Jeremy P. Cheadle
Summary: This study identified associations between MROH5 and neutropenia in colorectal cancer patients treated with oxaliplatin and fluoropyrimidine chemotherapy, as well as validated other potential biomarkers for personalized treatment. Despite extensive genome-wide analyses, common variants with modest effects associated with toxicities were lacking.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
F. Petrelli, E. Rulli, R. Labianca, S. Lonardi, G. Rosati, K. Dotti, M. Ronzoni, N. Pella, V Pusceddu, M. Banzi, M. G. Zampino, M. Yasmina, P. Marchetti, M. Cantore, A. Zaniboni, L. Rimassa, L. Ciuffreda, D. Ferrari, V Zagonel, E. Maiello, A. Sobrero
Summary: The TOSCA study compared different durations of adjuvant chemotherapy in high-risk stage II and stage III colon cancer patients and found no significant difference in overall survival between the 3-month and 6-month treatment arms.
ANNALS OF ONCOLOGY
(2021)
Article
Surgery
Vittoria Matilde Piva, Maria Caterina De Grandis, Irene Sole Zuin, Valentina Angerilli, Floriana Nappo, Rita Alfieri, Selma Ahcene Djaballah, Sabina Murgioni, Francesca Bergamo, Matteo Fassan, Michele Valmasoni, Sara Lonardi
Summary: This review summarizes the current evidence on the use of liquid biopsy in gastroesophageal cancer, focusing on the detection of ctDNA in the postoperative setting and its potential role as a guide for treatment decision.
UPDATES IN SURGERY
(2023)
Article
Oncology
Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, Sara Lonardi, Marina Macchini, Mariacristina Di Marco, Guido Giordano, Enrico Vasile, Mario Scartozzi, Silvia Bozzarelli, Silvia Noventa, Maria Grazia Rodriquenz, Anna Maria Militello, Ilario Giovanni Rapposelli, Ingrid Garajova, Stefania De Lorenzo, Barbara Merelli, Alessandro Bittoni, Lisa Salvatore, Letizia Procaccio, Chiara Paratore, Andrea Spallanzani, Umberto Peretti, Monica Niger, Elisa Giommoni, Ilaria Bernardini, Emiliano Tamburini, Katia Bernardino, Laura Forti, Maria Maddalena Valente, Stefano Cascinu, Michele Milella, Michele Reni
Summary: This study demonstrates the beneficial role of platinum agents in PDAC patients with gBRCA1-2pv, both in second-line treatment and as part of early 3- and 4-drug platinum-based chemotherapy combinations, providing improved survival outcomes.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Julien Taieb, Sara Lonardi, Jayesh Desai, Gunnar Folprecht, Claire Gallois, Eduardo Polo Marques, Sadya Khan, Claire Castagne, Harpreet Wasan
Summary: The combination of encorafenib and cetuximab is well tolerated in most patients with metastatic colorectal cancer, with the majority of adverse events being mild-to-moderate in severity, occurring early in treatment, and resolving rapidly, except for rare cases of nephrotoxicity.
CLINICAL COLORECTAL CANCER
(2023)
Article
Oncology
Mario Caccese, Anna Maria Saieva, Valentina Guarneri, Sara Lonardi, Massimo Cacco, Vanna Chiarion Sileni, Michele Gottardi, Eleonora Mioranza, Francesca Bergamo, Antonella Brunello, Vittorina Zagonel, Patrizia Benini
Summary: Routine testing for SARS-CoV-2 in asymptomatic and fully vaccinated cancer patients during treatment did not appear to be cost-effective. Out of 2439 cancer patients screened, only 2.17% tested positive, and 92.5% had their cancer treatment discontinued as a precaution.
Article
Oncology
Vincenzo Nasca, Francesco Barretta, Francesca Corti, Sara Lonardi, Monica Niger, Maria Elena Elez, Marwan Fakih, Priya Jayachandran, Aakash Tushar Shah, Massimiliano Salati, Elisabetta Fenocchio, Lisa Salvatore, Chiara Cremolini, Javier Ros, Margherita Ambrosini, Giacomo Mazzoli, Rossana Intini, Michael J. Overman, Rosalba Miceli, Filippo Pietrantonio
Summary: In this study of 331 patients with metastatic colorectal cancer treated with immune checkpoint inhibitors, it was found that certain immune-related adverse events (irAEs) could affect patient survival, with some having a protective effect and others having a harmful effect. The study proposed a simple model to evaluate the impact of irAEs on treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Camilla Lisanti, Debora Basile, Silvio Ken Garattini, Annamaria Parnofiello, Carla Corvaja, Francesco Cortiula, Elisa Bertoli, Elena Ongaro, Luisa Foltran, Mariaelena Casagrande, Paola Di Nardo, Giovanni Gerardo Cardellino, Gianpiero Fasola, Angela Buonadonna, Nicoletta Pella, Giuseppe Aprile, Fabio Puglisi
Summary: Recent evidence suggests the important role of immune system and cancer cells crosstalk. Gender-related immune system composition may affect immune response, chemotherapy and immunotherapy efficacy, and risk of immune-related adverse events. This study found that high monocyte-to-lymphocyte ratio (MLR) is an unfavorable independent prognostic factor in males and females with metastatic colorectal cancer.
Article
Oncology
Margherita Rimini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa, Francesca Salani, Sara Lonardi, Fabio Piscaglia, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Marta Schirripa, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This study analyzed the efficacy of atezolizumab plus bevacizumab versus Lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) class B. The results showed that Lenvatinib had a longer overall survival (OS) compared to atezolizumab plus bevacizumab in patients with CP B HCC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Floriana Nappo, Lorenzo Fornaro, Luca Pompella, Silvia Catanese, Daniele Lavacchi, Andrea Spallanzani, Alessandro Cappetta, Marco Puzzoni, Sabina Murgioni, Giulia Barsotti, Giuseppe Tirino, Antonio Pellino, Caterina Vivaldi, Antonia Strippoli, Giuseppe Aprile, Samantha Di Donato, Elena Mazza, Michele Prisciandaro, Lorenzo Antonuzzo, Vittorina Zagonel, Stefano Cascinu, Ferdinando De Vita, Sara Lonardi
Summary: This retrospective study on 265 patients treated with FLOT regimen showed that high microsatellite instability (MSI-H) and mismatch repair deficient (dMMR) have a positive prognostic role and better outcome in locally advanced gastric cancer (GC) patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Medicine, General & Internal
Michele Montrone, Gerardo Rosati, Vito Longo, Annamaria Catino, Raffaella Massafra, Annalisa Nardone, Francesco Pesola, Elisabetta Sara Montagna, Ilaria Marech, Pamela Pizzutilo, Domenico Galetta
Summary: Lung cancer is the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80% of cases. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic and early-stage NSCLC. However, the elderly face challenges in treatment due to comorbidities and reduced organ function. Despite less toxicity compared to chemotherapy, ICIs may be less effective in patients older than 75, possibly due to immunosenescence. This review explores the role of immunotherapy in elderly NSCLC patients, considering the biological aspects of immunosenescence.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Matteo Donadon, Angela Palmisano, Mariano Bizzarri, Roberto Ceriani, Luigi Veneroni, Gabriele Donati, Davide Tassinari, Massimo Giuseppe Viola, Emiliano Tamburini, Guido Torzilli
Summary: In this study, the impact of oocyte extract supplementation on quality of life (QoL) after liver surgery was evaluated. The treatment group showed improvements in health, mental, and psychological status, while the placebo group either did not change or experienced impairments compared to baseline.
Article
Oncology
Valentina Zampiga, Ilaria Cangini, Erika Bandini, Irene Azzali, Mila Ravegnani, Alessandra Ravaioli, Silvia Mancini, Michela Tebaldi, Gianluca Tedaldi, Francesca Pirini, Luigi Veneroni, Giovanni Luca Frassineti, Fabio Falcini, Rita Danesi, Daniele Calistri, Valentina Arcangeli
Summary: PVs and LPVs in BRCA1/2 genes are associated with a high risk of breast and/or ovarian cancer, and more BRCA1/2 variants have recently been found to be linked to pancreatic cancer. Inherited factors, particularly deleterious variants of BRCA2, play a role in 10% to 20% of pancreatic cancers. The frequency of BRCA1/2 germline alterations varies among ethnic groups, and the accurate estimation of PVs/LPVs variants in Italian HBOC families is still uncertain. This study aims to determine the prevalence of a BRCA2 PV in a specific cohort of HBOC patients and their relatives from the eastern coast of Emilia Romagna, Italy, and provides important evidence for genetic counseling and surveillance programs due to the increased risk of pancreatic and breast cancer.
Article
Oncology
Andrea Casadei-Gardini, Francesco Leone, Giovanni Brandi, Mario Scartozzi, Nicola Silvestris, Daniele Santini, Luca Faloppi, Massimo Aglietta, Maria Antonietta Satolli, Alessandro Rizzo, Sara Lonardi, Giuseppe Aprile, Lorenzo Fornaro
Summary: Cholangiocarcinoma is a rare tumor that affects the liver biliary tree with poor prognosis. This study analyzed a large dataset of cholangiocarcinoma patients receiving systemic chemotherapy over a period of almost 20 years to understand their survival trends.
FRONTIERS IN ONCOLOGY
(2023)
Article
Nutrition & Dietetics
Manlio Monti, Andrea Prochowski Iamurri, David Bianchini, Chiara Gallio, Luca Esposito, Daniela Montanari, Silvia Ruscelli, Chiara Molinari, Flavia Foca, Alessandro Passardi, Giovanni Vittimberga, Paolo Morgagni, Giovanni Luca Frassineti
Summary: This study aimed to investigate the association between routine blood parameters, inflammatory response markers, sarcopenia, adipose tissue depletion, and compliance to neoadjuvant/perioperative chemotherapy for gastric cancer. The results showed that changes in platelet to lymphocyte ratio (PLR) were associated with treatment interruption, while fat loss and sarcopenia were not related to compliance.
Article
Oncology
Stefania Gori, Alessandra Fabi, Catia Angiolini, Monica Turazza, Piermario Salvini, Gianluigi Ferretti, Elisabetta Cretella, Lorenzo Gianni, Claudia Bighin, Angela Toss, Claudio Zamagni, Patrizia Vici, Costanza De Rossi, Antonio Russo, Giancarlo Bisagni, Antonio Frassoldati, Lucia Borgato, Anna Cariello, Claudia Cappelletti, Roberto Bordonaro, Saverio Cinieri, Alessandra Modena, Matteo Valerio, Maria Francesca Alvisi, Irene De Simone, Francesca Galli, Eliana Rulli, Anna Santoni, Fabrizio Nicolis
Summary: This study evaluated the rate of early breast cancer patients treated with neoadjuvant systemic therapy in Italy. It found that 13.9% of patients received this treatment. Various factors such as menopausal status, tumor size, lymph node involvement, grade, HER2 status, and triple negative subtype were associated with the decision to administer neoadjuvant therapy. The choice of therapy also varied based on the patient's phenotype subgroup.
Article
Biochemistry & Molecular Biology
Gianmaria Miolo, Angela Buonadonna, Simona Scalone, Davide Lombardi, Lara Della Puppa, Agostino Steffan, Giuseppe Corona
Summary: Specific bile acid metabolic profiles may be associated with the prognosis of mSTS patients, while prognostic factors for mSTS are currently very limited.